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Abstract
Introduction: Post-menopausal women with estrogen receptor (ER) positive breast cancer receive adjuvant 
chemotherapy and endocrine therapy sequentially since tamoxifen may antagonise the cytotoxicity of 
chemotherapy drugs. With increased use of aromatase inhibitors (AIs) in place of tamoxifen, the potential use 
of concomitant chemo-endocrine treatments with the AI letrozole, before clinical trials are undertaken, requires 
evaluation.  
Methods: MCF7-aro cells expressing the aromatase gene were treated with letrozole, doxorubicin and 
docetaxel.  The effects of different drug concentrations, drug combinations and scheduling on cytotoxicity and 
aromatase activity were investigated.  Key receptor, cell cycle regulation and apoptosis proteins were examined 
by immunoblotting.
Results: Administration of letrozole with either doxorubicin or docetaxel resulted in increased levels of 
cytotoxicity under all treatment schedules (add in, sequential or simultaneous drug administration) with the 
greatest anti-proliferative effect observed using concomitant treatment (letrozole first with chemotherapy added 
in). The inhibitory effect of letrozole on aromatase activity was unchanged by the addition of doxorubicin 
or docetaxel.  Letrozole treatment resulted in decreased HER2 expression and addition of doxorubicin and 
docetaxel to letrozole led to elevated ER-b levels.
Conclusions: In vitro, letrozole, unlike tamoxifen, enhances the cytotoxicity of both doxorubicin and docetaxel. 
This supports the prospect of trials using letrozole with chemotherapy in postmenopausal women with ER 
positive breast cancer.  
Introduction
Breast cancer accounts for almost one in three (31%) of 
all cancer cases in UK women (excluding non-melanoma 
skin cancer) and causes over 12,100 deaths each year 
[1].  However, despite a rising incidence, survival from 
breast cancer is increasing, due to earlier detection and 
improved treatment.
Two thirds of breast cancers occur in post-menopausal 
women and within this group, estrogen receptor  alpha 
BioDiscovery | www.biodiscoveryjournal.co.uk December 2012 | Issue 6 | 22
Letrozole enhances chemotherapy in breast cancer
(ERα) positive cancers constitute some 80%.  Advances 
in treatment including the endocrine agent tamoxifen, 
chemotherapies and more recently aromatase inhibitors 
[2, 3] have contributed significantly to the disease free 
survival of such patients.
Tamoxifen is a selective estrogen receptor modulator 
(SERM), antagonizing estrogen receptor function by 
competitively binding to the ERα, blocking estrogen 
binding and thus inhibiting cellular proliferation [4]. 
However, due to the partial agonistic properties of 
tamoxifen on ERα, tamoxifen treatment is associated with 
a number of adverse side effects including endometrial 
cancer and also an increased risk of thromboembolism 
[5, 6].  Although a greater disease free survival was 
observed after 10 years of tamoxifen compared to 5 years 
adjuvant therapy [7], prolonged tamoxifen use may also 
lead to acquired tumour resistance and coupled with the 
significant side effects has led to increasing interest in 
aromatase inhibitors (AIs) [8].  
Aromatase inhibitors (AIs) block the aromatase 
enzyme, preventing the conversion of androstenedione 
to estrone and subsequently estradiol [4, 9, 10], without 
any direct activity on ERα. AIs thus block estrogen 
synthesis including the autocrine and paracrine estrogen 
production from peri-tumoral stromal cells, which 
may play a role in tumour proliferation [11, 12].  The 
AIs anastrozole and letrozole have demonstrated an 
increased disease free survival compared to tamoxifen 
[13, 14].  Subsequent trials have demonstrated increased 
activity and/or survival advantage of letrozole over 
tamoxifen in the neoadjuvant [15], adjuvant [14], 
extended adjuvant [16]  and advanced disease [17] 
settings .  Moreover, letrozole given subsequent to 5 
years of tamoxifen therapy also improved disease free 
survival [18]. Letrozole is currently the only AI licensed 
for use in the neo-adjuvant, adjuvant, extended adjuvant 
and metastatic settings in post-menopausal ERα positive 
patients. 
With this increased use of letrozole for 
postmenopausal women in the neoadjuvant, adjuvant 
and advanced disease settings, the sequencing of AIs 
with chemotherapy agents requires further appraisal. 
However, meta-analyses have demonstrated that 
tamoxifen,  added to chemotherapy, was of marginal 
benefit in older women [19].  Furthermore, consensus 
trials data [20, 21] , and in vitro experimental evidence 
[22-24] suggested that tamoxifen may be interacting 
antagonistically with some cytotoxic agents.  The 
phase III SWOG-8814 / INT-0100 trial, comparing 
cyclophosphamide, doxorubicin and fluorouracil (CAF) 
followed by tamoxifen (CAF-T) or CAF with concurrent 
tamoxifen (CAFT), reported sequential chemotherapy 
followed by tamoxifen was superior to concurrent 
tamoxifen and anthracycline based therapy [25].  
Given this background, tamoxifen treatment has 
been prescribed post-chemotherapy in the adjuvant 
setting; despite the differing modes of action, aromatase 
inhibitors are also prescribed in a similar manner. Given 
recent interest in combining AIs with chemotherapy, this 
study sought to test in an in vitro model system whether 
chemo-endocrine therapy using a widely prescribed AI, 
letrozole, in combination with two standard breast cancer 
chemotherapy agents, doxorubicin and docetaxel, holds 
clinical potential.  To test this hypothesis, using MCF7-
aro cells over-expressing the aromatase gene [26], 
letrozole, docetaxel or doxorubicin were administered 
under a range of experimental conditions. The cytotoxic 
effects, aromatase activity, and proteins involved in ERα 
signalling, in cell cycle regulation and apoptosis were 
studied to elucidate and compare the effects of letrozole 
in this setting.  
Materials and methods
Cell culture
The MCF7-aro cell-line, stably transfected with the 
human aromatase gene and thus dependent on androgens 
for proliferation, was maintained in Dulbecco’s Modified 
Eagle Media +phenol-red (+DMEM) supplemented 
with 10% fetal calf serum, 1% penicillin/streptomycin 
and 700mg/ml G418 (Invitrogen Ltd., Renfrewshire, 
UK) [26][21].  For experiments the cells were purged 
of any residual steroids and the estrogenic effects 
of phenol-red by sub-culturing for 4 days in DCC 
media (Dulbecco’s Modified Eagle Media -phenol-red 
[-DMEM] supplemented with 3% charcoal stripped-
FCS [Hyclone, Thermo-Fisher, Leicestershire, UK], 2% 
HEPES[1M] and 1% L-Glutamine[200mM].  Media was 
changed after 2 days. All cells were cultured at 37°C 
in humidified incubator with 5% CO2 and periodically 
checked for Mycoplasma according to manufacturer’s 
instructions (MycoAlert®, Cambrex, Berkshire, UK).
Cell Viability Assays 
MCF7-aro cells at a confluency of  80% were steroid 
deprived for 4 days, trypsinised with trypsin/EDTA 
lacking phenol-red (Invitrogen Ltd., Renfrewshire) and 
seeded into 96-well plates (1.2 x 104 cells/well) in 200μl 
DCC media. After 24 hours the media was removed 
and steroid depleted media (DCC) containing 25nM 
4-Androstenedione (AD) (Sigma-Aldrich, Dorset, UK) 
was added to the cells to induce proliferation.  Vehicle 
control (EtOH) or compounds either singly (letrozole, 
doxorubicin, docetaxel, tamoxifen) or in combinations 
(letrozole, doxorubicin, docetaxel) were added in 
media for either  2 days (48 hours), 4 days (96 hours) 
or 6 days depending on the experiment (Table 1). 
Tamoxifen (4-Hydroxytamoxifen) and docetaxel were 
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obtained from Sigma-Aldrich, Dorset, UK, doxorubicin 
from Pharmachemie B.V, Haarlem, Netherlands, and 
letrozole from Novartis, UK. Pre-treatment exposure 
was for 2 days followed by media removal and further 
treatment for 4 days.  After the appropriate length of 
time, cells were assayed for cell viability utilizing the 
CellTiter 96® Aqueous One Solution Cell Proliferation 
Assay according to the manufacturer’s instructions 
(Promega, Southampton, UK).  Briefly, media was 
removed and 100μl of AD media containing 20μl MTS 
added to each well and incubated for 3 hours at 37°C 
5% CO2.  Absorbance was read at 490nm with a 96-well 
SpectraMax 190 UV/Vis plate reader. Cells treated with 
AD were taken to represent 100% proliferation and all 
drug-treated cells were expressed relative to this.
Western Blotting  
Cells were seeded at 1x107 in 60mm tissue-culture 
plates in 4ml media and cultured for 24 hours.  Cells 
were then treated in DCC media containing 25nM AD 
+/– drug (IC50 concentrations) for either 24h, or 2 days 
pre-treatment with letrozole followed by a further 24h 
treatment. Cells were harvested by washing twice in ice 
cold PBS prior to lysis in 180ml of complete protein 
lysis buffer (150mM NaCl, 1% NP40, 50mM Tris HCL 
pH 8.0, 50mM NaF, 5mM EDTA pH 8.0 with freshly 
added complete protease inhibitor [Roche, Sussex, UK]). 
Cell lysates were vortexed for 2 min then centrifuged 
Table 1. Three drug regimens using letrozole, doxorubicin and 
docetaxel in a simultaneous, sequential or add-in approach. 
Regimen
First 48 hours 
(2 days)
Subsequent 96 
hours (4 days) 
to total 6 days
Simultaneous Letrozole Letrozole
Letrozole + 
doxorubicin
Letrozole + 
doxorubicin
Letrozole + 
docetaxel
Letrozole + 
docetaxel
Letrozole + 
doxorubicin + 
docetaxel
Letrozole + 
doxorubicin + 
docetaxel
Sequential Letrozole Letrozole 
Letrozole Doxorubicin 
Letrozole Docetaxel 
Letrozole Doxorubicin + 
docetaxel 
Add in Letrozole Letrozole
Letrozole Letrozole + 
doxorubicin
Letrozole Letrozole + 
docetaxel
Letrozole Letrozole + 
doxorubicin + 
docetaxel
at 14,000rpm for 20 min at 4°C. Protein concentrations 
in the supernatants were determined by Bradford assay 
(Bio-Rad Protein Assay, Bio-Rad Laboratories, Herts, 
UK) and equal amounts of protein used for western blot 
analysis.  Immunoblot analysis was performed using the 
following primary antibodies: Anti-ER-a, anti-EphA2 
(Sigma-Aldrich, Dorset, UK); anti b-Actin, anti-Bax 
(Abcam Ltd, Cambridge, UK); anti-P21waf1 (Calbiochem, 
Nottingham, UK); anti-Bcl2 (Dako Ltd, Cambridgeshire, 
UK) anti-HER-2, anti-c-Fos, anti-VEGF, anti-ER-β 
(Novacastra Laboratories Ltd, Newcastle Upon-Tyne); 
anti-p53 (DO-1) (Lane Group, Ninewells Hospital, 
Dundee, UK). Polyclonal rabbit-anti-mouse IgG HRP 
and polyclonal swine-anti-rabbit IgG were used as 
secondary antibodies (Dako Ltd, Cambridgeshire, UK). 
Samples were separated by SDS-PAGE on 4-12% Bis-
Tris NuPage gels with either MOPS or MES buffers 
using the Novex mini cell system (Invitrogen, Glasgow, 
UK), after which they were transferred to Immobilon 
PVDF membranes (Millipore, Buckinghamshire, UK) 
and blocked in 0.1% (v/v) PBS-Tween-20 (PBST) 
with 5% (w/v) dry skimmed milk (PBSTM) for 1h at 
RT.  The membrane was washed 3 times for 15 min 
with PBST before incubation with primary antibodies 
at 4°C overnight. Membranes were further washed (3 x 
5 min) in PBST before incubation with the appropriate 
HRP labeled secondary antibody in PBSTM for 1 h at 
room temperature. Membranes were washed (3 x 5 min) 
in PBST, developed by ECL™ Solution (Amersham, 
Buckinghamshire, UK) and exposed to autoradiography 
film (Fuji x-ray film) prior to development in a Fuji 
X-ray Imaging Developer 800A.
Aromatase Assay  
Aromatase enzymatic activity was assayed using a 
modification of the method described by Zhou et al. 
[26] and exploits release of [3H]H2O from the substrate 
3H-19, hydroxyl-stenedione (3H-AD) in the presence 
of aromatase.  Cells were seeded at 3.5 x 104 per well 
in 96-well tissue-culture plates in 200μl DCC media 
and cultured for 24 hours.  Cells were then treated 
in DCC media containing 25nM AD +/– drug (IC50 
concentrations) for 72h. The media was removed 
and 120μl of 4.8 pmol of 1b-3H(N)-androst-4-ene-3, 
17-dione (NET-926; NEN PerkinElmer, Bucks, UK) 
as substate (specific activity, 23.5 Ci/mmol) in DCC 
media was added. Controls of 120μl DCC media and 
vehicle (0.0012% EtOH) were also included. After 6 
hours of incubation 110μl of this media was removed 
and extracted into 220μl of chloroform. Samples were 
vortexed for 30 seconds and centrifuged at 1700g 
for 10 min. Residual steroids were then removed by 
addition of 100μl of the aqueous phase to 100μl of 0.5% 
charcoal vegetal active/0.5% dextran T70 suspension. 
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Samples were again vortexed for 30 seconds and 
centrifuged at 15,000g for 5 min before 150μl of the 
resultant upper-phase was removed and added to 4ml 
of OPTI-FLUOR scintillation fluid (Anachem Ltd, 
Bedfordshire, UK). The [3H]H2O released was counted 
on a 3H channel scintillation counter reading at 10 min 
intervals on a Beckman LS6500 scintillation counter 
(Beckman Coulter UK Ltd., High Wycombe, UK). 
The protein concentration of the cells in each well was 
also determined, using the Bradford assay. Briefly, 
cells were washed twice in PBS, prior to addition of 
20μl of 50mM Tris-HCl, pH 7.2 followed by 200μl 
of Bradford reagent (Bio-Rad Protein Assay, Bio-Rad 
Laboratories, Herts, UK).  Samples were incubated 
for 5 min at room temperature and the absorbance was 
read at 595nm on a 96-well SpectraMax 190 UV/Vis 
plate reader with SOFTmax® PRO Softwear, Molecular 
Devices Ltd.  Aromatase activity was calculated from 
the disintegrations per minute as picomoles of estrogen 
produced by milligrams of protein per hour (pmol/
mg/h).
Statistical analysis
Statistical analysis was performed using Minitab 
statistical software (Minitab Inc., version 15.1.0.0) for 
descriptive statistics (mean, standard deviation, 95% 
confidence interval, etc.). 2-sample t-tests were used to 
test the differences in mean values. A p-value of <0.05 
was considered statistically significant.
Results
To establish the drug concentrations that produced a 
50% inhibition of cellular growth when steroid deprived 
MCF7-aro cells were stimulated to proliferate with 25nM 
AD and then treated with the drug for 96 hours, MTS 
assays were performed with the letrozole, doxorubicin, 
docetaxel and tamoxifen. IC50 values were compiled 
from 3 separate experiments, each done in quadruplicate 
(Table 2), then the IC50 values used in all subsequent 
experiments.  
Table 2. Drug  IC50 values. IC50 values for doxorubicin, docetaxel, 
letrozole and tamoxifen in MCF7-aro cells stimulated to proliferate 
with 25nM AD and then drug treated for 96 hours.  Values shown were 
derived from 3 separate experiments, each done in quadruplicate ± 
SEM.
Drug IC50 (µM)
Docetaxel 5.0 ± 1.0
Doxorubicin 6.0 ± 0.7
Letrozole 1.0 ± 0.03
Tamoxifen 2.5 ± 0.2
As expected, letrozole inhibited cellular growth and 
significantly inhibited aromatase activity (p=0.006) 
(Figure 1). Conversely, tamoxifen did not inhibit 
aromatase activity and indeed an increase in aromatase 
activity was noted in the MCF7-aro cells (p=0.044) (data 
not shown). 
Figure 1. Aromatase activity of MCF7-aro cells in DCC media 
containing 25nM AD and treated with 1µM letrozole for 72 hours. 
Error bars ± 95% CI.     
Combining chemo-endocrine therapies in different 
schedules
The effects of combining letrozole with the 
chemotherapeutic agents doxorubicin and/or docetaxel 
and the effects of scheduling of the agents was 
examined.  Cells were pre-treated with letrozole for 48 
hours and this was then followed by chemotherapy alone 
(Sequential) or chemotherapy in the presence of further 
endocrine agent (Add-in).  In addition, cells were not 
pre-treated with any agent and allowed to proliferate to 
80% confluence prior to treatment with chemotherapy 
and endocrine agent together (Simultaneous). For each 
combination, three separate MTS assays were each done 
in quadruplicate after a total of 6 days in culture (Figure 
2).
Chemotherapy effects
Cell survival with doxorubicin alone or docetaxel alone 
was reduced by combining the two drugs (Figure 2a).
Simultaneous treatment (letrozole + chemotherapy 
together)
Simultaneous treatment against growing cells with 
letrozole and either doxorubicin or docetaxel, or 
the combination chemotherapy, displayed enhanced 
cytotoxicity compared to letrozole alone (p<0.0001 in 
each case)(Figure 2b).  
Sequential treatment (letrozole alone followed by 
chemotherapy alone) 
Sequential treatment showed that letrozole followed 
by either doxorubicin or docetaxel or doxorubicin and 
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Figure 2. Combining chemo-endocrine therapies in different schedules.  MCF-7aro cells in DCC media containing 25nM AD were seeded 
into 96 well plates and then after a total of 6 days in culture MTS cytotoxicity assays were performed. The percentage of cells surviving 
relative to the cells treated solely with AD was calculated and plotted.  Results shown are the average of three separate MTS assays each done 
in quadruplicate.  Error bars ± 95% CI.  Drugs were applied at their IC50 values: doxorubicin – 6µM, docetaxel – 5µM, letrozole – 1µM.  (2a) 
Chemotherapy controls – Cells were grown for 48 hours and then treated solely with chemotherapy agents for 96 hours.  (2b) Simultaneous 
– Cells were grown for 48 hours and then treated with both chemotherapy and endocrine agents together for a further 96 hours as indicated. 
(2c) Sequential – Cells were pre-treated with letrozole for 48 hours and then treated with chemotherapy for 96 hours. (2d) Add-in – Cells 
were pre-treated with letrozole for 48 hours and then treated with chemotherapy in the presence of further letrozole for 96 hours.  
docetaxel combined, resulted in significantly enhanced 
cytotoxocity compared to letrozole alone (p<0.0001 for 
each comparison) (Figure 2c). 
Add-in pre-treatment (letrozole first + chemotherapy 
added in) 
Add-in pre-treatment with letrozole followed by further 
letrozole and the addition of either doxorubicin or 
docetaxel  or combined doxorubicin and docetaxel 
significantly enhanced the cytotoxic effects of  the drugs 
(p<0.0001) (Figure 2d). 
In all the treatment schedules tested, letrozole 
provided a greater cytotoxic effect when combined 
with chemotherapy, either doxorubicin, docetaxel or 
the two agents combined, than if letrozole was given 
alone.  Add-in treatment of letrozole with chemotherapy 
provided the most efficacious method for reducing cell 
survival followed by sequential treatment and lastly 
by simultaneous treatment. Add-in treatment (Figure 
2d) also displayed the biggest differential between 
chemotherapy alone (Figure 2a) and a chemotherapy-
letrozole combinations. 
Chemo-endocrine therapy with letrozole does not 
alter aromatase activity
As letrozole appeared to synergize with both doxorubicin 
and docetaxel to promote increased efficacy of these 
agents, aromatase activity was re-examined. Letrozole 
with either doxorubicin or docetaxel, alone or in 
combination, did not significantly alter the inhibitory 
effect of letrozole on aromatase activity (Figure 3). 
Molecular changes
To examine the effects of letrozole at a molecular level, a 
series of western blots for proteins involved in estrogen 
receptor signaling (ER-a, ER-b, HER-2, VEGF and 
EphA2; Figure 4a) and key proteins involved in cell 
cycle and apoptosis were also examined (p21, p53, Bax, 
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Figure 3. Aromatase activity of MCF7-aro cells in DCC media 
containing 25nM AD treated with 1µM letrozole in the presence of 
either 6µM doxorubicin, 5µM docetaxel or both chemotherapeutics. 
Assays were carried out after 72 hours of incubation. Error bars ± 
95% CI. 
Table 3. Summary of changes in protein expression with drug treatment of MCF7-aro.
Letrozole Doxorubicin Docetaxel Doxorubicin+
Docetaxel
Letrozole+
Doxorubicin
Letrozole+
Docetaxel
Letrozole+
Doxorubicin+
Docetaxel
ER ↑ ↓ ↑ ↓ ↑
ER ↔ ↔ ↑ ↑ ↑ ↑ ↑
HER-2 ↓ ↔ ↔ ↔ ↔ ↔ ↔
VEGF ↓ ↓ ↔ ↓ ↔ ↑ ↑
EphA2 ↔ ↑ ↓ ↑ ↑ ↑ ↑
P21 ↔ ↑ ↔ ↑ ↑ ↑ ↑
P53 ↔ ↑ ↔ ↑ ↑ ↑ ↑
Bax ↔ ↔ ↔ ↑ ↑ ↑ ↑
Bcl-2 ↔ ↔ ↔ ↔ ↔ ↔ ↔
c-fos ↔ ↓ ↔ ↔ ↔ ↔ ↔
Bcl-2 and c-fos; Figure 4b)(Table 3). 
ER-a increased and HER-2 levels decreased with 
letrozole. Protein levels of VEGF decreased but EphA2 
and ER-b did not alter. p21, p53, bax, bcl2 and c-fos 
levels were unchanged with letrozole treatment. 
Cells treated with doxorubicin or docetaxel, as 
predicted from their different mechanisms of action, 
displayed very different protein profiles.  Doxorubicin 
treated cells showed increased p21, p53 and EphA2 
expression and reduced expression of ER-a, c-fos and 
VEGF was noted.  Docetaxel treated cells displayed 
decreased EphA2 expression.  When the two agents were 
combined, smaller increases in p21 were observed, ER-
b, and EphA2 were elevated but ER-a levels decreased.
Treatment with letrozole and doxorubicin resulted 
in increased levels of ER-b but neither drug added 
individually altered ER-b expression.  However, when 
docetaxel was added with letrozole the expression of 
most proteins examined was increased (Table 3). 
Figure 4. Examples of western immunoblotting of MCF7-
aro cells in DCC media containing 25nM AD treated with 1µM 
letrozole, 6µM doxorubicin, 5µM docetaxel or drug combinations 
as indicated, for 24 hours. (4a) Expression of proteins involved 
in estrogen receptor signalling. (4b) Expression of cell cycle and 
apoptosis related proteins. β-actin was used as a loading control in 
all cases.  
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Application of the two chemotherapeutics with 
letrozole resulted in a similar pattern of protein expression 
with increases in p21, p53, EphA2 and ER-b expression.
Discussion 
Using estrogen receptor positive, aromatase enzyme 
transfected MFC7-aro cells as a model system and 
cytotoxicity assays, we have demonstrated that 
letrozole, when combined with the commonly used 
chemotherapeutic agents doxorubicin and/or docetaxel, 
displayed increased cytotoxicity compared to letrozole 
alone.  This was true whether the chemo-endocrine cocktail 
of drugs were applied sequentially, simultaneously or 
added-in, although add-in application (letrozole first 
+ chemotherapy added in) was most potent in terms 
of effect.  Furthermore, the addition of doxorubicin, 
docetaxel or both chemotherapies along with letrozole 
did not compromise aromatase inhibition by letrozole. 
If extrapolated into an in vivo clinical situation, these 
data suggest at least no detriment in using letrozole 
contemporaneously with doxorubicin and/or docetaxel 
chemotherapy, with the potential clinical convenience 
of starting letrozole therapy while awaiting the add-in of 
chemotherapy. Indeed, a combination of letrozole with 
these agents may have enhanced clinical potential in the 
neoadjuvant, adjuvant or advanced disease settings.  This 
contrasts with the established clinical trials evidence that 
concurrent tamoxifen and anthracycline based therapy is 
not beneficial [25]. 
Letrozole treatment alone resulted in modest changes 
in the proteins examined with only HER-2 and VEGF 
showing downregulated expression.  However, given 
the cross-talk between HER-2 with several signal 
transduction pathways, alterations in HER-2 expression 
may underpin the increased cytotoxicity observed with 
letrozole [27].
When letrozole was added to docetaxel the effects 
on protein expression were usually additive.  In 
contrast, combining letrozole with doxorubicin gave 
data dissimilar to that predicted from the drugs applied 
individually.  With either letrozole or doxorubicin, ER-b 
protein expression was unchanged, but when combined 
together ER-b levels increased.  Again, this highlights the 
complex cross-talk pathways operating at cellular levels 
and may also reflect the multiple mechanisms of action of 
doxorubicin compared with those of docetaxel [28, 29].
Application of both chemotherapies together with 
letrozole resulted in similar changes in the protein 
profiles compared to the untreated controls.  Given that 
the proteins examined are primarily involved in cell cycle 
control or apoptosis, and a substantial reduction in cell 
viability was observed, this result may not be unexpected. 
However, this effect was not simply due to the actions 
of the combined chemotherapies as the protein profiles 
obtained in the presence of letrozole were different 
compared to the doxorubicin plus docetaxel regimen. 
For example, with letrozole + doxorubicin + docetaxel, 
ER-b  levels were increased reflecting a potential role in 
ER signaling [30, 31].
ER-b is expressed in both normal and malignant 
breast tissue, although it tends to show lower expression 
in tumours [30].  Re-introduction of ER-b into ER-a 
positive breast cancer cells has demonstrated that it has 
opposing actions to ER-a, causing an anti-proliferative 
effect [30].  High expression of ER-b has also been 
correlated with good prognosis and prolonged disease 
free survival, albeit in response to tamoxifen (reviewed 
in [31]). Thus, up-regulation of ER-b,  by combining 
letrozole with doxorubicin and docetaxel, may provide 
one plausible explanation at the molecular level for the 
enhanced efficacy of this regime. 
Combining the AI letrozole with the chemotherapy 
agents doxorubicin and/or docetaxel in vitro enhances 
the cytotoxic and therapeutic potential.  In contrast 
to the clinical trials experience with tamoxifen, the 
potential use of letrozole sequentially, or concurrently, 
with doxorubicin and/or docetaxel chemotherapy within 
the neoadjuvant, adjuvant and advanced disease setting 
warrants further investigation in the clinical setting. As a 
first step, a trial of docetaxol and doxorubicin +/– letrozole 
for ER positive primary breast cancer in postmenopausal 
women is attractive to detect the potential enhanced 
in vivo efficacy of adding letrozole to a known active 
chemotherapeutic regimen. Clinical endpoints of disease 
response and biomarker studies (informed by the data 
presented here) would be informative for subsequent 
adjuvant trials combining letrozole with chemotherapy 
rather than extrapolating from historic, tamoxifen-based 
data.
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